Chadi invites a trio of lymphoma experts to weigh the importance of the POLARIX trial – which was presented at the ASH Annual Meeting and looked at frontline therapy for patients with DLBCL. Matthew Matasar, MD, Memorial Sloan Kettering Cancer Center, co-authored publication of the POLARIX study “Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma” in the New England Journal of Medicine and defends its results with guests Liz Brem, MD, UC Irvine, and Daniel Landsburg, MD, University of Pennsylvania. Can polatuzumab vedotin supplant conventional R-CHOP as the standard of care for previously untreated DLBCL? As they work through the details of the study, the experts share whether they believe the data supports an immediate standard-of-care change or if more research is needed.
Dr. Joe Mikhael, Chief Medical Officer of the International Myeloma Foundation (IMF) and Professor at TGen, takes us beyond his medical career to explore the personal experiences that have shaped his journey in oncology. Dr. Mikhael discusses the IMF’s targeted strategies for reducing health disparities among diverse ethnic and racial groups affected by myeloma, shedding
Tom Beer, Chief Medical Officer of the Multi-Cancer Early Detection (MCED) program at Exact Sciences, delves into the groundbreaking science behind MCED tests, which use advanced biomarkers for early detection of multiple cancer types. On this Healthcare Unfiltered episode, he explains who may be eligible for these tests, how to interpret results to avoid unnecessary
In this special episode, I give up the microphone to guest host Kelly Ryerson, who takes over the show asking questions about my new book “The Cancer Journey.”
